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Abstract
Background 
Concerning diabetic nutritional therapy, Calorie Restriction (CR) and Low Carbohydrate 
Diet (LCD) have been on discussion. Authors continue clinical research related to CR, LCD, 
Morbus(M) value and insulin secretion. 
Subjects and Methods 
Subjects were 42 patients (63.4 years on average) with type 2 diabetes mellitus 
(T2DM) with its immunoreactive insulin (IRI) =<5μU/mL. Methods included CR breakfast 
with carbohydrate 70g (Carbo70), Insulinogenic Index (IGI) calculation and daily profile 
of blood glucose.
Results
Subjects showed median data; M value 207, HOMA-R 1.0, Delta Ratio of IGI for 
Carbo70 is 0.12 [0.08–0.22], Area under the Curves (AUC) Ratio of IGI-Carbo70 is 3.0 
[2.2-4.8]. Divided into 3 groups due to HbA1c, median glucose and M value was 133mg/
dL, 227 mg/dL, 345mg/dL and 15.8, 207, 587, respectively. Delta and AUC Ratio of IGI-
Carbo70 in 3 groups were 0.17, 0.10, 0.10and5.2, 2.9, 1.9, respectively. There were 
significant correlations between M value and Delta ratio / AUC ratio, in which the latter 
has higher degree of significance.
Discussion and Conclusion
Among 3 groups, the distribution was overlapped in Delta-IGI, and was rather 
divided in AUC-IGI. Consequently, the latter method seems to be rather superior. These 
results would be the fundamental data, and further development of research is expected.
Keywords: Area Under the Curves (AUC), Insulinogenic index (IGI), type 2 diabetes 
mellitus (T2DM), Morbus value (M value), Delta ratio of IGI, AUC ratio of IGI
Abbreviation 
AUC: Area under the Curve
IGI: Insulinogenic Index 
T2DM: Type 2 diabetes mellitus 
M value: Morbus value 
IRI: immunoreactive insulin
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Introduction
On the historical point of view, noteworthy medical 
problems have changed from infectious diseases to non-
communicable diseases. For some decades, metabolic 
syndrome (Met-S) has been more prevalent worldwide[1,2,3].
They are crucial medical and social problems with lots of 
influencing factors such as lifestyle, age, meal, exercise, 
habitual status, socioeconomic status, and others [4]. Met-S 
has increasing and leading to several arteriosclerotic diseases 
such as hypertension and diabetes [5].
As to Diabetes, it is also increasing rapidly in developed 
countries and also developing countries. It has macro- and 
micro-angiopathic complications, including large vessels of 
brain, heart, lower leg, as well as retinopathy, neuropahy and 
nephropaphy [6]. 
For diabetes management, there have been recently 
changes of comments from medical society such as American 
Diabetes Association (ADA) and American College of 
Physicians (ACP) [7, 8]. The main point for the controversy was 
concerning the ideal HbA1c level in various situations. On 
contrast, standards of medical care were proposed by 
International Diabetes Federation (IDF). Among them, the 
intake and counting amount for carbohydrate would be 
emphasized [9].
The problem of carbohydrate intake has been continued 
for long. Nutritional therapy for diabetes can be generally 
classified into 2 patterns. One is Calorie Restriction (CR) diet, 
and another is Low Carbohydrate Diet (LCD) [10,11].The 
former means fat and calorie restriction, and the latter means 
decreased amount of carbohydrate which has been known 
for its clinical effects such as weight reduction and others.
Originally, LCD was initiated by Bernstein and others in 
Western countries, and has been spread widely after that [12]. 
On contrast in Japan, authors and colleagues began LCD in 
early period [13]. We have treated lots of diabetic patients on 
LCD, and continued to present clinical research on CR and 
LCD [14, 15]. Moreover, we had reported the efficacy of LCD, 
useful three types of LCD (super, standard, petit), 
pathphysiological role of ketone bodies in the axis of fetus, 
placenta, newborn and pregnant mother [16]. 
Through our clinical research on CR and LCD, we have 
provided formula diet of CR and LCD and performed the 
examination. Taking the most advantages of our research 
protocol, we have reported the trial of breakfast including 
70g of carbohydrate for the evaluation of pancreas function, 
similar to 75g OGTT [17]. In previous study, we analyzed the 
method using the Delta (increment) of glucose and 
immunoreactive insulin (IRI). 
In current study, we have developed the research 
furthermore, by calculating by area under the curves (AUC) 
for the responses of blood glucose and IRI. The purpose of 
this report would be the comparison of the analysis methods 
between AUC and Delta, as well as the comparison of the 
meal tolerance test (MTT) developing in recent clinical studies.
Subjects and Methods
In this study, subjects were 42 patients with type 2 
diabetes mellitus (T2DM). They were admitted to the hospital 
for further evaluation and treatment for T2DM. As to the 
background of the patients, we enrolled the subjects who are 
compatible to the following condition: i) the diagnosis is 
T2DM, ii)T1DM or slow progressive type of DM are excluded, 
iii) IRI is 5μU/mL and less than 5 IU/ml in the morning after 
overnight fasting, iv) body mass index (BMI) is 35 and less 
than 35. According to the value of HbA1c, subjects were 
divided into 3 groups and analyzed. 
Methods are on our protocol for diabetes with the meal 
of CR and LCD. In this study, the following procedures were 
used as follows. 
i)  As to our research protocol, patients are to take CR on 
day 1 and 2, and LCD after day 3, with 1400 cal/day 
each. This study includes carbohydrate loading test on 
day 2 and daily profile of blood glucose 7 times a day 
on day 2. 
ii)  After overnight fasting on the morning of Day 2, basal 
biomarkers were measured such as complete blood 
count, liver and kidney function, lipids, blood glucose, 
IRI and so on.
iii)  After drawing blood samples, patients took breakfast 
with 70g of carbohydrate. Regarding this breakfast, its 
PFC ratio was protein 15%, fat 25%, carbohydrate 60%, 
with 1400 kcal/day. It is along to the standard guideline 
in nutritional therapy which was proposed by Japan 
Diabetes Society (JDS) [18].
iv)  Thirty minutes after breakfast, blood sample was 
drawn for blood glucose and IRI. During 30 minutes 
from the breakfast, patients were told to keep still on 
sitting position. 
v)  Daily profile of blood glucose was investigated on Day 
2. The clock time was 08, 10, 12, 14, 17, 19, 22h, 7 times 
a day. Average blood glucose value and also Morbus(M) 
value were calculated.
Ratio of insulin/glucose response
From the data of glucose and IRI on 0 and 30 min, two 
ratios were calculated and investigated.
Insulinogenic index (IGI) has been known to evaluate 
insulin secretion and pancreas function. Its formula is delta 
(increment) of insulin (30min – 0 min) / delta (increment) of 
blood glucose (30min – 0min). In this paper, we call it ‘Delta 
Ratio of IGI for Carbo70’.
In response to glucose loading, IRI and glucose increase. 
Another evaluating method includes usage of Area under the 
Curves (AUC) of the both. The ratio between IRI and glucose 
would be called as ‘AUC Ratio of IGI for Carbo70’.
From described above, two ratios are defined in the 
following. Delta Ratio of IGI for Carbo70 is calculated as (IRI at 
30min – IRI at 0min) (μU/mL) / (Glucose at 30min – Glucose at 
0min) (mg/dL). 
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Similarly, AUC Ratio of IGI for Carbo70 is calculated as 
(AUC of IRI for 0-30min) (μU/mL x h)/ (AUC of glucose for 
0-30min) (mg/dL x h). 
Daily profile of blood glucose
Regarding to the glucose variability, we checked the daily 
profile of blood glucose on day 2 for 7 times a day. The clock 
time was 08, 10, 12, 14, 17, 19, 22h. According to these data, 
average blood glucose in a day on Day 2 and also M value 
were calculated. There were previous data concerning the 
comparison between sampling of 7 times and 20 times. From 
this result, both would have compatible data with similar data 
from continuous glucose monitoring (CGM) [19-21]. 
Morbus value 
Morbus (M) value has been known as one of the biomarker 
indicating average blood glucose level and also the mean 
amplitude of glycemic excursions (MAGE) [22, 23]. In other 
words, it can suggest how high the blood glucose is and how 
large the swinging degree of blood glucose is. The level of M 
value is calculated by the method of logarithmic 
transformation, which means the deviation of glucose 
from ideal glucose value [23, 24].
The formula of the M value is as follows: Firstly, M = MBS + 
MW: M value is the total of MBS and MW. In addition, MW is 
maximum blood glucose-minimum glucose)/20. Thirdly, MBS is 
the mean of MBSBS. Summarized above, MBSBS is the individual 
M-value for each blood glucose, calculated as (absolute value of 
[10 × log (blood glucose level/120)])3 [22-24].
Generally, the obtained data of the M value is evaluated 
in the following: less than 180 would be normal range, from 
180 to 320 would be borderline, more than 320 would be 
abnormal.
Statistical analysis
In this study, obtained data were shown by mean and 
standard deviation, and also the median and quartile of 25% 
/ 75% due to the biomarkers. The latter are described as 
median [25%–75%]. Regarding the statistical calculation, we 
used the correlation coefficients, according to the Spearman 
test, which has been utilized on analytical evaluation [25].
Ethical Standard
Current research was conducted in compliance with the 
ethical principles based upon the Declaration of Helsinki. 
Moreover, additional commentary was performed in 2004 
General Assembly Tokyo, Japan. It was conducted with 
Personal Information Protection Law and in reference to 
“Standards for the Implementation of Clinical Trials (GCP), an 
ordinance of the Ministry of Health, Labour and Welfare No. 
28 of March 27, 1997. In addition, there was the “Ethical 
Guidelines for Epidemiology Research” by the Ministry of 
Education, Culture, Sports, Science and Technology and the 
Ministry of Health, Labour and Welfare.
Authors and colleagues had an ethical committee including 
physician, nurse, pharmacist and other experts in the legal 
specialty. We have discussed and confirmed that current study is 
valid and agreed with all members. Moreover, informed consents 
and written paper agreements have been taken from the 
subjects. This study has been registered by National University 
Hospital Council of Japan (ID: #R000031211).
Results
Basal data
Basal data of the subjects were shown in Table 1. Average 
data was 63.4 years in age, 8.0% in HbA1c, 230 mg/dL in 
glucose, respectively. Median data was 207 in Morbus value, 
1.0 in HOMA-R, 80 mg/dL in Triglyceride, respectively.
Responses of Glucose and insulin for Carbo70 were 
shown in Table 2. From the data of 0 min and 30 min, Delta 
Ratio of IGI for Carbo70 and AUC ratio of IGI for Carbo70 were 
0.12[0.08–0.22] and 3.0 [2.2-4.8], respectively. 
Table 1. Subjects and basal data
Mean ± SD median [25% - 75%]
number (M/F) 42 (25/17) 42 (25/17)
age (years old) 63.4 ± 11.0 66 [60 - 69]
HbA1c (%) 8.0 ±1.7 7.9 [6.5 - 9.1]
average glucose (mg/dL) 230 ± 84.8 228 [158 - 294]
Morbus value 294 ±297 207 [39.9 - 468]
HOMA-R 1.2 ±0.7 1.0 [0.9 - 1.6]
HOMA-β 14.1 ±9.9 11.1 [7.7 -16.9]
Triglyceride (mg/dL) 118 ± 96.0 80.0 [63.3 - 140]
HDL-C (mg/dL) 72.7 ±20.6 69.0 [56.3 - 85.0]
LDL-C (mg/dL) 133 ±36.8 136 [106 -157]
Table 2. Responses of Glucose and IRI for Carbo70
mean ± SD median [25% - 75%]
Response of blood glucose
before ( 0 min) 170 ± 57.3 156 [117- 212]
after (30 min) 218 ± 62.6 209 [159 - 275]
increment (⊿) 50.0 ± 23.1 46.0 [32.3 - 62.5]
Response of Insulin
before ( 0 min) 2.9 ±1.1 3.0 [2.2 - 3.8]
after (30 min) 11.0 ± 8.7 8.7 [6.3 - 12.0]
increment (⊿) 8.1 ± 8.5 6.4 [3.8 - 8.9]
Delta-IGI for carbo70
⊿IRI/⊿BG 0.19 ± 0.22 0.12 [0.08 - 0.22]
AUC-IGI for carbo70
AUC-IRI/AUC-BG 4.0 ± 3.0 3.0 [2.2- 4.8]
IRI: immunoreactivity of Insulin, Carbo70: Carbohydrate 70g
IGI: Insulinogenic index, AUC: Area Under the Curve
Comparison among 3 groups
Subjects were divided into 3 groups due to the value of 
HbA1c with 14 cases each. HbA1c value in Low, Middle and 
High group was 5.4%–6.8%, 6.9%-8.5% and 8.6%-11.8%, 
respectively. Median value was 6.3%, 7.9% and 9.8%, 
respectively.
Glucose and Morbus value in three groups were shown in 
Figure 1. In the 3 groups, the median level in average glucose 
was 133mg/dL, 227 mg/dL and 345 mg/dL, respectively. The 
median level in M value was 15.8, 207, 587, respectively.
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Figure 1. Average glucose and Morbus value in three groups
1a: Average blood glucose
1b: Morbus value
Delta ratio of IGI for Carbo70 and AUC ratio of IGI for 
Carbo70 in 3 groups were shown in Figure 2. In the 3 groups, the 
median level in Delta ratio of IGI was 0.17, 0.10, and 0.10, 
respectively. Similarly, the median level in AUC ratio of IGI was 
5.2, 2.9, 1.9, respectively. Compared the distribution of the data 
in both ratios, the former revealed rather overlapped, while the 
latter revealed rather clear difference among 3 groups.
Figure 2. Comparison of Delta and AUC ratio of IGI
2a: Delta ratio of IGI for carbo 70(0-30min)  
2b: AUC ratio of IGI for carbo70(0-30min)
Delta ratio vs AUC ratio
Correlations between M value and Delta ratio of IGI / AUC 
ratio of IGI were shown in Figure 3.There were significant 
correlations in both, where Delta ratio is p<0.05, and AUC 
ratio is p<0.01. The latter has higher degree of significance.
Figure 3. Comparison of correlation for Delta and AUC ratio
3a: Delta ratio of IGI and Morbus value 
3b: AUC ratio of IGI and Morbus value
Discussion
Concerning diabetes, research for pathophysiological 
function and practice for nutritional treatment have been 
important and crucial for future therapy. In these aspects, 
authors have continued clinical practice for lots of patients 
with T2DM so far. Authors and colleagues have developed 
useful LCD meal education through the activity of Japan Low 
Carbohydrate Diet Promotion Association [13]. For example, 
we proposed three types of LCD for everyone. They are petit-
LCD, standard-LCD, super-LCD. These 3 LCD include the ratio 
of carbohydrate as 40%, 26%, 12%, respectively. 
Regarding the medical research reports about diabetes, 
LCD and CR, we have already investigation from several 
aspects including the usefulness of M value [14, 15, 26].
Our previous achievements have been involved in this 
report. In the case of CR diet, breakfast has 70g of carbohydrate 
due to the standard CR formula by Japanese Diabetes 
Association (JDA) [18]. This carbohydrate load seems to 
stimulate the responses of glucose and insulin to the enough 
degree, although it includes not only carbohydrate but also 
fat and protein. 
Thus, the research for diabetic patients using the meal of 
CR and LCD has been performed so far. It always included the 
analyses of useful biomarker of the M value, which represents 
both average blood glucose level and the mean amplitude of 
glycemic excursions (MAGE) [17, 27].
Regarding current study, biomarkers were classified into 
three groups due to HbA1c value and investigated. In the box 
plot analysis for average blood glucose, the median glucose 
in 3 groups was 133 mg/dL, 227 mg/dL, 345 mg/dL, 
respectively. These median value and also quartile values 
(25% and 75%) indicate that the distribution of 3 groups 
would be divided in rather satisfactory degree with less 
overlapped region, suggesting the compatible relationship 
between HbA1c and average blood glucose.
In the case of M value, the median level in 3 groups was 
15.8, 207, 587, respectively. The characteristic point of M 
value would be the large difference in numerical values. This 
is from the mathematic reason of the M value, in which the 
degree of elevated glucose and increased swinging of glucose 
are described. It is useful for us to evaluate by one numerical 
value for two factors.
There are some differences of distribution of 3 groups in 
Delta ratio and in AUC ratio, respectively. In Delta ratio of IGI, 
3 groups seem to be rather overlapped. On the other hand, In 
AUC ratio of IGI, 3 groups seems to be rather divided. From 
these difference, both research ways have been useful in the 
clinical research, but AUC ratio seems to be a little superior to 
Delta ratio as an analysis method of IGI.
Several methods are available for examining the insulin 
response to carbohydrate loading in order to examine 
pancreatic function or secretion of insulin [28]. Conventionally, 
Intravenous Glucose Tolerance Test (IVGTT) and oral glucose 
tolerance test (OGTT) has been widely known [29]. In recent 
years, a method of ingesting a meal including protein, fat and 
carbohydrate has been introduced and adopted in clinical 
practice and research. 
This research method has been called as a mixed-meal 
test (MMT). There was a representative report of MMT [30]. 
Participants ingested high-protein Boost-HP (237ml, Vevey, 
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Switzerland) consisting of 33 g of carbohydrate, 15 g of 
protein, and 6 g of fat. This liquid has the PFC ratio which is 
25:20:55. In this report, patients with positive auto antibodies 
showed the results that Delta IGI for Carbo 33g would be 1.6 
in average. 
In addition to MMT, there is another technical term, meal 
tolerance test (MTT). This is similar to 75g oral glucose 
tolerance test (GTT). There were MTT reports for the clinical 
research studies [31]. MTT has been usually provided as 
breakfast. One example of breakfast of MTT includes 450 kcal 
including PFC = 15:35:50, with salt 1.6g [31]. Calculated from 
this information, carbohydrate dose would be estimated 56g 
in the served breakfast. 
In other MTT report, the protocol was that breakfast of 
500-kcal meal with 55% carbohydrate was given to patients 
with T2DM [32]. The amount of carbohydrate 69g is similar to 
our protocol with 70g of carbohydrate. Then, these data 
would become useful reference in comparison with our data. 
According to their results, glucose and IRI (0 to 30min) would 
be 167 to 230mg/dL, 12 to 37μU/mL, respectively. Calculated 
from these, Delta ratio of IGI is 0.39, and AUC ratio of IGI is 
12.3. These data seems to be similar to our results in the low 
HbA1c group.
There is a recent report during 120 min for OGTT [33]. 
According to the responses of glucose and insulin, subjects 
were categorized into four groups, which are normal, insulin-
late, insulin/glucose-late and insulin-very late. The results 
showed that AUC-glucose significantly differed among 4 
groups, but AUC-IRI did not significantly differed [33]. These 
findings could become reference data for the future MTT 
research.
Regarding the limit of our research, several factors would 
be considered. Our study is involved in the analyses for the 
insulin secretion concerning the study in this area. However, 
the existence of insulin resistance will be explored, using 
some relevant biomarkers. For example, both HOMA-R and 
HOMA-β will be applied to the investigation. Consequently, 
the relationship among related factors would be explored in 
the future study.
Conclusion
In summary, we examined the reaction of blood glucose 
and insulin for a meal containing 70g of carbohydrate utilizing 
standard CR breakfast. Although Delta and AUC analyses are 
both meaningful, the latter method may be somewhat with 
superiority. These results would be the fundamental related 
data in this field, and further development of related research 
is expected.
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